Omnicell Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell or view top-rated stocks.

Wall Street analysts have given Omnicell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Omnicell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Omnicell is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Omnicell.

Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings results on Thursday, July, 29th. The company reported $0.97 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.55 by $0.42. The business had revenue of $272.74 million for the quarter, compared to analysts' expectations of $267.20 million. Omnicell had a net margin of 6.05% and a trailing twelve-month return on equity of 11.06%.
View Omnicell's earnings history.

Omnicell's stock was trading at $77.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OMCL stock has increased by 103.2% and is now trading at $157.27.
View which stocks have been most impacted by COVID-19.

Omnicell updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of $3.650-$3.750 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.590. The company issued revenue guidance of $1.10 billion-$1.12 billion, compared to the consensus revenue estimate of $1.10 billion.

8 equities research analysts have issued 12 month price targets for Omnicell's stock. Their forecasts range from $84.00 to $188.00. On average, they expect Omnicell's stock price to reach $138.07 in the next year. This suggests that the stock has a possible downside of 12.2%.
View analysts' price targets for Omnicell or view top-rated stocks among Wall Street analysts.

150 employees have rated Omnicell CEO Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

Some companies that are related to Omnicell include Cerner (CERN), Cortexyme (CRTX), Allscripts Healthcare Solutions (MDRX), Vocera Communications (VCRA), HealthStream (HSTM), Computer Programs and Systems (CPSI), Athena Technology Acquisition (ATHN) and Mirage Energy (MRGE).
View all of OMCL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.98%), Vanguard Group Inc. (10.72%), Conestoga Capital Advisors LLC (3.35%), State Street Corp (3.12%), Clearbridge Investments LLC (2.50%) and Neuberger Berman Group LLC (2.45%). Company insiders that own Omnicell stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell.

OMCL stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Wells Fargo & Company MN, Price T Rowe Associates Inc. MD, BlackRock Inc., Ziegler Capital Management LLC, Federated Hermes Inc., ArrowMark Colorado Holdings LLC, and Legal & General Group Plc. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, James T Judson, Peter J Kuipers, Randall A Lipps, Robin Gene Seim, and Scott Peter Seidelmann.
View insider buying and selling activity for Omnicell or view top insider-selling stocks.

OMCL stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Clearbridge Investments LLC, APG Asset Management N.V., Vanguard Group Inc., Neuberger Berman Group LLC, Principal Financial Group Inc., Eagle Asset Management Inc., and Bridgewater Associates LP.
View insider buying and selling activity for Omnicell or or view top insider-buying stocks.

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OMCL stock can currently be purchased for approximately $157.27.

Omnicell has a market capitalization of $6.84 billion and generates $892.21 million in revenue each year. The company earns $32.19 million in net income (profit) each year or $1.74 on an earnings per share basis.

Omnicell employs 2,860 workers across the globe.

The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.

Omnicell was founded in 1992.

The official website for Omnicell is www.omnicell.com.

Omnicell is headquartered at 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at (650) 251-6100 or via email at [email protected].